RABI-767

About Lamassu Biotech

Lamassu Biotech is a private, clinical-stage biotech advancing a pipeline of novel small molecule therapeutics with an emphasis on accelerated development timelines. Its lead programs include SA53, a first-in-class oncology candidate targeting p53 wild-type tumors in Phase I/II, and RABI-767 for acute pancreatitis, which has progressed to Phase II. The company's strategy centers on a collaborative, translational research model that bridges academia and industry to de-risk and expedite the path from discovery to definitive clinical testing.

About Arrivo BioVentures

Arrivo BioVentures, founded in 2018 and based in Raleigh, NC, is a private biotech holding company with a portfolio of two clinical-stage drug candidates acquired through licensing and partnerships. The company leverages an experienced management team with a strong track record in fundraising and exits to advance novel therapies for major depressive disorder (SP-624) and predicted severe acute pancreatitis (RABI-767). Its strategy centers on in-licensing and developing disease-modifying therapies with new mechanisms of action for conditions with high unmet need.

Therapeutic Areas

Other Acute Pancreatitis Drugs